跳转至内容
Merck
CN

I6658

Sigma-Aldrich

Isradipine

≥98% (HPLC), solid

别名:

4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H21N3O5
CAS号:
分子量:
371.39
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

描述

Store under nitrogen

质量水平

方案

≥98% (HPLC)

表单

solid

颜色

yellow

溶解性

DMSO: >10 mg/mL

创始人

Novartis

储存温度

2-8°C

SMILES字符串

COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C

InChI

1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3

InChI key

HMJIYCCIJYRONP-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Isradipine has been used to explore neuroprotective activity.

生化/生理作用

Isradipine is considered as an active calcium channel blocker, used to treat hypertension.
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.

特点和优势

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Philip F Copenhaver et al.
Disease models & mechanisms, 4(5), 634-648 (2011-05-21)
A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the
Rodrigo Almeida Simões et al.
Analytical and bioanalytical chemistry, 399(7), 2435-2443 (2011-01-20)
An enantioselective liquid chromatographic method using two-phase hollow fiber liquid-phase microextraction (HF-LPME-HPLC) was developed for the determination of isradipine (ISR) enantiomers and its main metabolite (pyridine derivative of isradipine, PDI) in microsomal fractions isolated from rat liver. The analytes were
Vincent Malaterre et al.
Drug development and industrial pharmacy, 35(4), 433-439 (2008-11-08)
Push-pull osmotic systems have been developed to deliver poorly soluble drugs in a modified-release fashion. The aim of this study was to investigate the influence of the tablet core factors on the drug release kinetics and loadability. The release kinetics
C Savio Chan et al.
Movement disorders : official journal of the Movement Disorder Society, 25 Suppl 1, S63-S70 (2010-02-27)
Parkinson's disease (PD) is a common neurodegenerative disorder of unknown etiology. There is no cure or proven strategy for slowing the progression of the disease. Although there are signs of pathology in many brain regions, the core symptoms of PD
Tanya Simuni et al.
Movement disorders : official journal of the Movement Disorder Society, 25(16), 2863-2866 (2010-09-08)
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门